Share

The key list

Powered by

Leading emerging companies in Europe by R&D Expenditure

This month our power industry key list brings you the 15 largest emerging companies in Europe by R&D Expenditure, as ranked by GlobalData's Power Intelligence Centre. All numbers as of April 2020.

Company nameAnnual R&D Expenditure ($million)Headquarters locationNumber of employees

F. Hoffmann-La Roche Ltd

11,294Switzerland97,735

Novartis AG

8,681Switzerland103,914

Sanofi

6,951France104,226

Bayer AG

6,191Germany104,711

AstraZeneca Plc

5,266UK70,600

GlaxoSmithKline Plc

4,969UK99,437

Merck KGaA

2,621Germany52,140

Allergan Plc

2,266Ireland17,400

Novo Nordisk AS

2,148Denmark43,258

UCB SA

1,370Belgium7,495

Mylan NV

569UK35,000

H. Lundbeck AS

501Denmark5,569

Alkermes Plc

425Ireland2,300

Galapagos NV

381Belgium725

Idorsia Pharmaceutical Ltd

378Switzerland636

Share this article

Go to article: Home | An (in)active pill problemGo to article: EditorialGo to article: SHL Group Company InsightGo to article: Scandinavian HealthGo to article: ContentsGo to article: NSFGo to article: NewsGo to article: AlmacGo to article: Covid-19 executive briefing by GlobalDataGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Digital biomarkers are emerging as important predictive tools to support the gloGo to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: Almost 70 potential Covid-19 drug and experimental compound candidates identifiedGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: Risk assessment of Covid-19 on patients suffering from IBDGo to article: Zenatek Go to article: The pharma industry briefingGo to article: FargoGo to article: Another bump in the road for mumps treatmentGo to article: Last TechnologyGo to article: From Covid-19 to SARS: what becomes of the whistleblowers?Go to article: ButterworthGo to article: Peptomyc: the quest for a ‘universal’ cancer treatmentGo to article: Q&A: is pharma ready to address the health effects of climate change?Go to article: Modality SolutionsGo to article: Not-so-inactive ingredients: a sore spot for patients?Go to article: Beyond M&As: will 2020 be the year of the spin-off? Go to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Q&A with Genocea: improving cancer treatment with precise, personalised targetsGo to article: MimotopesGo to article: Pharma Playbook: an inside look at Signals Analytics vast therapeutic database Go to article: ILC Dover Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue